持股变动声明
Design Therapeutics(DSGN)06-18 05:05
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017240 Size: 5 KB 网页链接
简介:Design Therapeutics, Inc.于2017年12月18日根据特拉华州法律成立。他们是一家临床阶段的生物制药公司,开创了新的小分子治疗候选物,称为GeneTACs,旨在用于疾病治疗。某些核苷酸重复扩增疾病,如FA,可导致特异性mRNAs表达降低;在其他疾病,如强直性肌营养不良1型(DM1)、FECD和Huntington病,核苷酸重复扩增可导致毒性基因产物的产生,通常与病理性核病灶有关。他们的基因被设计成选择性地与基因重复序列结合,通过恢复或阻断mRNA转录来调节基因表达,并恢复细胞健康。作为一个平台,他们相信GeneTACs在单基因核苷酸重复序列扩增疾病中具有广泛的潜在适用性。
今开:4.32 | 昨收:4.24 |
最高:4.56 | 最低:4.27 |
涨停价: | 跌停价: |
总市值:246318370 |
Design Therapeutics(DSGN)06-18 05:05
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017240 Size: 5 KB 网页链接
Design Therapeutics(DSGN)06-18 04:15
$Design Therapeutics(DSGN)$ 8-K Current report, item 5.07 Accession Number: 0000950170-24-074243 Act: 34 Size: 170 KB 网页链接
Design Therapeutics(DSGN)04-26 04:45
$Design Therapeutics(DSGN)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-048411 Act: 34 Size: 15 MB 网页链接
Design Therapeutics(DSGN)06-18 05:05
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017237 Size: 5 KB 网页链接
Design Therapeutics(DSGN)04-26 04:35
$Design Therapeutics(DSGN)$ DEF 14A Other definitive proxy statements Accession Number: 0000950170-24-048385 Act: 34 Size: 1 MB 网页链接
Design Therapeutics(DSGN)06-18 05:05
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017239 Size: 5 KB 网页链接
Design Therapeutics(DSGN)04-26 04:35
$Design Therapeutics(DSGN)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-048399 Act: 34 Size: 290 KB 网页链接
Design Therapeutics(DSGN)06-18 05:05
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017241 Size: 5 KB 网页链接
Design Therapeutics(DSGN)06-18 05:15
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-074363 Size: 5 KB 网页链接
Design Therapeutics(DSGN)05-09 04:15
$Design Therapeutics(DSGN)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-055645 Act: 34 Size: 425 KB 网页链接
BT财经2023-08-17 17:45
【BT机构股评】生物制药公司Design Therapeutics股票评级下调
SVB Securities将生物制药公司Design Therapeutics的股票评级从“跑赢大盘”下调至“与大盘持平”,并将其目标价从22美元下调至6美元。此前,该公司公布的DT-216治疗弗里德赖希共济失调(Friedreich's ataxia)的i期MAD研究数...查看全文
薛定锷之猫2023-02-21 06:27
$Design Therapeutics(DSGN)$ 贝壳兄弟在退出?大幅减仓查看全文
anos2021-05-06 15:29
$Design Therapeutics(DSGN)$
Design Therapeutics(DSGN)-基本面介绍 网页链接查看全文
牛唐2021-04-30 22:14
$Design Therapeutics(DSGN)$ 又一个30%的收益,棒棒哒。$蔚来(NIO)$ $百度(BIDU)$查看全文
chuminhua2021-03-28 12:07
3月26日,Design Therapeutics、Edgewise Therapeutics、Ikena Oncology和Universe Pharmaceuticals(大自然药业)都在周五登陆纳斯达克。前三家分别收获了超过1亿美元的资金,其中Design募集了2.4亿美元,Edgewise净赚了1.76亿美元,Ikena则成功募集了1.25亿美元。Universe打入2500万美元。
D...查看全文
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-074363 Size: 5 KB 网页链接
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017237 Size: 5 KB 网页链接
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017238 Size: 5 KB 网页链接
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017240 Size: 5 KB 网页链接
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017241 Size: 5 KB 网页链接
$Design Therapeutics(DSGN)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-24-017239 Size: 5 KB 网页链接
$Design Therapeutics(DSGN)$ 8-K Current report, item 5.07 Accession Number: 0000950170-24-074243 Act: 34 Size: 170 KB 网页链接
$Design Therapeutics(DSGN)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-055788 Act: 34 Size: 6 MB 网页链接
$Design Therapeutics(DSGN)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-055645 Act: 34 Size: 425 KB 网页链接
$Design Therapeutics(DSGN)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-048411 Act: 34 Size: 15 MB 网页链接